serine/threonine kinase 10Genealiases: LOK · PRO2729
Q-omics provides the consensus-scored STK10 profile across patient tissues and cancer cell-line models. STK10 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, STK10 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, STK10 protein abundance shows 28,385 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, HNSC, and LSCC as cancer lineages where STK10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STK10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STK10 survival associations across molecular data types. STK10 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STK10 RNA expression–survival associations across cancer types. High STK10 expression shows unfavorable associations in UVM, LUSC, HNSC, LAML and KIRP, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for STK10 RNA expression.
This table summarizes STK10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for STK10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STK10 shows lower tumor expression in LUSC and higher tumor expression in HNSC, KIRC, STAD, LIHC and ESCA. The HNSC box plot shows higher STK10 RNA expression in tumor versus normal tissue (log2 FC = +1.506, t-test p < 0.001).
This table shows molecular features associated with STK10 in patient tissues and cancer cell lines. In patient samples, STK10 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, STK10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BONE.
